E. Coquan, J. Lequesne, E. Colomba, J. Frenel, C. Abdeddaim, V. D'Hondt, M. Castera, S. Abadie-Lacourtoisie, C. Dubot, P. Brachet, A. Leconte, B. Clarisse, Florence Joly
{"title":"评估cabozantinib治疗铂治疗失败后晚期或转移性宫颈癌的安全性和有效性的II期研究(CABOCOL研究)","authors":"E. Coquan, J. Lequesne, E. Colomba, J. Frenel, C. Abdeddaim, V. D'Hondt, M. Castera, S. Abadie-Lacourtoisie, C. Dubot, P. Brachet, A. Leconte, B. Clarisse, Florence Joly","doi":"10.1136/ijgc-2022-esgo.30","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":114847,"journal":{"name":"Cervical cancer","volume":"124 1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"2022-RA-579-ESGO A phase II study assessing safety and efficacy of cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure (CABOCOL study)\",\"authors\":\"E. Coquan, J. Lequesne, E. Colomba, J. Frenel, C. Abdeddaim, V. D'Hondt, M. Castera, S. Abadie-Lacourtoisie, C. Dubot, P. Brachet, A. Leconte, B. Clarisse, Florence Joly\",\"doi\":\"10.1136/ijgc-2022-esgo.30\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":114847,\"journal\":{\"name\":\"Cervical cancer\",\"volume\":\"124 1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cervical cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2022-esgo.30\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cervical cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2022-esgo.30","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
2022-RA-579-ESGO A phase II study assessing safety and efficacy of cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure (CABOCOL study)